Abstract:Vitamin B 6 is important in fetal development, but little is known of the vitamin B 6 status of pregnant women and newborns in North America and potential modifying factors. This prospective study determined maternal and cord plasma concentrations of pyridoxal 5′ phosphate (PLP; an indicator of vitamin B 6 status) in a convenience sample of 368 Canadian pregnant women and their newborns. The association of maternal intake of vitamin B 6 and fetal genetic variants with cord plasma PLP and homocysteine concentra… Show more
“…Additionally, maternal folate and total B-12 concentrations declined between the first and second trimesters, whereas PLP concentration dropped across all trimesters. Similar results were found in pregnant Spanish women, in whom plasma folate and total B-12 concentrations decreased from 15 to 24–27 weeks of gestation 27 , and a significant decline in PLP concentration across trimesters was also reported in pregnant Canadian women 28 . Potential mechanisms involved in the decrease of the aforementioned B vitamins by trimester are likely related to increased mother-fetus transport, increased glomerular filtration and hemodilution due to the increment of blood volume during pregnancy 29 – 31 .…”
Increased first-trimester low-density lipoprotein (LDL-C) concentration has been associated with adverse pregnancy outcomes, such as gestational diabetes. The B vitamins folate, B-6, and total B-12 are key for the methyl group-dependent endogenous synthesis of phosphatidylcholine, which is needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of circulating LDL-C. Maternal B-vitamin concentration usually declines across trimesters. Whether changes in maternal B-vitamin concentrations are associated with total cholesterol (TC), triglycerides (TG), and lipoprotein concentrations is unknown. Therefore, we explored the association between plasma folate, vitamin B-6 in the form of pyridoxal 5′-phosphate (PLP), and total B-12 with serum TC, LDL-C, HDL-C, and TG concentrations across trimesters. This secondary analysis used data of a prospective pregnancy cohort study included apparently healthy adult women (n = 179) from Rio de Janeiro, Brazil. The biomarkers were measured in fasting blood samples collected at 5–13, 20–26, and 30–36 weeks of gestation. The associations between B vitamins and lipid concentrations across trimesters were explored using linear mixed-effect models. Among B vitamins, only plasma folate was positively associated with TC (β = 0.244, 95% CI 0.034–0.454) and LDL-C (β = 0.193, 95% CI 0.028–0.357) concentrations. The positive relationship of maternal folate and TC and LDL-C concentrations may indicate the importance of folate as a methyl donor for lipoprotein synthesis during pregnancy.
“…Additionally, maternal folate and total B-12 concentrations declined between the first and second trimesters, whereas PLP concentration dropped across all trimesters. Similar results were found in pregnant Spanish women, in whom plasma folate and total B-12 concentrations decreased from 15 to 24–27 weeks of gestation 27 , and a significant decline in PLP concentration across trimesters was also reported in pregnant Canadian women 28 . Potential mechanisms involved in the decrease of the aforementioned B vitamins by trimester are likely related to increased mother-fetus transport, increased glomerular filtration and hemodilution due to the increment of blood volume during pregnancy 29 – 31 .…”
Increased first-trimester low-density lipoprotein (LDL-C) concentration has been associated with adverse pregnancy outcomes, such as gestational diabetes. The B vitamins folate, B-6, and total B-12 are key for the methyl group-dependent endogenous synthesis of phosphatidylcholine, which is needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of circulating LDL-C. Maternal B-vitamin concentration usually declines across trimesters. Whether changes in maternal B-vitamin concentrations are associated with total cholesterol (TC), triglycerides (TG), and lipoprotein concentrations is unknown. Therefore, we explored the association between plasma folate, vitamin B-6 in the form of pyridoxal 5′-phosphate (PLP), and total B-12 with serum TC, LDL-C, HDL-C, and TG concentrations across trimesters. This secondary analysis used data of a prospective pregnancy cohort study included apparently healthy adult women (n = 179) from Rio de Janeiro, Brazil. The biomarkers were measured in fasting blood samples collected at 5–13, 20–26, and 30–36 weeks of gestation. The associations between B vitamins and lipid concentrations across trimesters were explored using linear mixed-effect models. Among B vitamins, only plasma folate was positively associated with TC (β = 0.244, 95% CI 0.034–0.454) and LDL-C (β = 0.193, 95% CI 0.028–0.357) concentrations. The positive relationship of maternal folate and TC and LDL-C concentrations may indicate the importance of folate as a methyl donor for lipoprotein synthesis during pregnancy.
“…Baseline biochemical outcomes are presented in Table 2; outcomes at endline and postpartum visits are presented in Table 3 (erythrocyte folate, serum folate and plasma UMFA) and online Supplementary Table (exploratory outcomes: vitamin B 12 , PLP, total homocysteine, cysteine, methionine, free choline and betaine). While cut-offs during pregnancy are not established, median concentrations of vitamin B 12 and PLP remained above cut-offs for deficiency in non-pregnant women (vitamin B 12 < 148 pmol/l and PLP < 20 nmol/l), and total homocysteine remained < 13 µmol/l (cut-off for hyperhomocysteinaemia) in all participants, at all visits (48,49) . No participants had erythrocyte folate (< 305 nmol/l) or serum folate (< 7 nmol/l) indicative of deficiency at any point (50) .…”
Folic acid supplementation is recommended during pregnancy to support healthy fetal development; (6S)-5-methyltetrahydrofolic acid [(6S)-5-MTHF] is available in some commercial prenatal vitamins an alternative to folic acid, but its effect on blood folate status during pregnancy is unknown. To address this, we randomized 60 pregnant individuals at 8-21 weeks’ gestation to 0.6 mg/day folic acid or (6S)-5-MTHF x 16-weeks. Fasting blood specimens were collected at baseline and after 16-weeks (endline). Red blood cell (RBC) and serum folate were quantified via microbiological assay (as globally recommended) and plasma unmetabolized folic acid (UMFA) via LC-MS/MS. Differences in biochemical folate markers between groups were explored using multivariable linear/quantile regression, adjusting for baseline concentrations, dietary folate intake, and gestational weeks. At endline (n=54), the mean ± SD (or median, IQR) RBC folate, serum folate, and plasma UMFA (nmol/L) in those supplemented with (6S)-5-MTHF versus folic acid, respectively, was: 1826 ± 471 and 1998 ± 421; 70 ± 13 and 78 ± 17; 0.5 (0.4, 0.8) and 1.3 (0.9, 2.1). In regression analyses, RBC and serum folate did not differ by treatment group; however, concentrations of plasma UMFA in pregnancy were 0.6 nmol/L higher (95% CI: 0.2-1.1) in those supplementing with folic acid as compared to (6S)-5-MTHF. In conclusion, supplementation with (6S)-5-MTHF may reduce plasma UMFA by ∼50% as compared to supplementation with folic acid, the biological relevance of which is unclear. As folate is currently available for purchase in both forms, the impact of circulating maternal UMFA on perinatal outcomes needs to be determined.
“…2 ) ( Ducker and Rabinowitz, 2017 , Bailey et al, 2015 , O’Leary and Samman, 2010 , Ueland, 2011 , Petersen et al, 20199 , Brosnan et al, 2019 ). Table 5 summarizes one-carbon metabolism cohort studies ( Petersen et al, 20199 , Ray et al, 2002 , Ray et al, 2007 , Visentin et al, 2016 , Visentin et al, 2016 , Fofou-Caillierez et al, 2019 , O’Malley et al, 2018 , Molloy, 2018 , Visentin et al, 2015 , Barzilay et al, 2018 , Plumptre et al, 2018 , Murphy et al, 2021 ) …”
Section: Resultsmentioning
confidence: 99%
“…Choline intake was less than adequate (<450 mg/d) in 87% of women ( Molloy, 2018 ) PERFORM cohort choline Dietary maternal choline status, not the fetal genotype, influences cord plasma concentrations of choline metabolites ( Visentin et al, 2015 ) PERFORM cohort carbon one elements There were no maternal differences in one-carbon nutrients/metabolites between GDM and control patients. ( Barzilay et al, 2018 ) PERFORM cohort B6 Vitamin B6 deficiency is uncommon, likely due to prevalent vitamin B6 prenatal supplement use ( Plumptre et al, 2018 ) Folic Acid RCT Clinical Trial (FACT) Ancillary Study Folic acid dose (1 or 5 mg) and One Carbon metabolism High dose FA in early pregnancy increases serum folate but not RBC folate concentrations; high dose FA may be supraphysiologic with no evidence of altered 1-carbon metabolism ( Murphy et al, 2021 ) Abbreviations : aOR adjusted odds ratio; B6 vitamin B6; B12 vitamin B12; FA folic acid; NTD neural tube defect; NS non-significant; RBC red blood cell. …”
More evidence is available for maternal intake, absorption, distribution, tissue specific concentrations, and pregnancy outcomes with folic acid (fortification/supplementation) during preconception – first trimester. This Quality Improvement prevention review used expert guidelines/opinions, systematic reviews, randomized control trials/controlled clinical trials, and observational case control/case series studies, published in English, from 1990 to August 2021. Optimization for an oral maternal folic acid supplementation is difficult because it relies on folic acid dose, type of folate supplement, bio-availability of the folate from foods, timing of supplementation initiation, maternal metabolism/genetic factors, and many other factors. There is continued use of high dose pre-food fortification ‘RCT evidenced-based’ folic acid supplementation for NTD recurrence pregnancy prevention. Innovation requires preconception and pregnancy use of ‘carbon one nutrient’ supplements (folic acid, vitamin B12, B6, choline), using the appropriate evidence, need to be considered. The consideration and adoption of directed personalized approaches for maternal complex risk could use serum folate testing for supplementation dosing choice. Routine daily folic acid dosing for low-risk women should consider a multivitamin with 0.4 mg of folic acid starting 3 months prior to conception until completion of breastfeeding. Routine folic acid dosing or preconception measurement of maternal serum folate (after 4–6 weeks of folate supplementation) could be considered for maternal complex risk group with genetic/medical/surgical co-morbidities. These new approaches for folic acid oral supplementation are required to optimize benefit (decreasing folate sensitive congenital anomalies; childhood morbidity) and minimizing potential maternal and childhood risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.